Q1 EPS Estimate for Mineralys Therapeutics Lifted by Analyst

Q1 EPS Estimate for Mineralys Therapeutics Lifted by Analyst

Mineralys Therapeutics, Inc. (NASDAQ:MLYS – Free Report) – Equities researchers at HC Wainwright increased their Q1 2026 EPS estimates for Mineralys Therapeutics in a research report issued on Monday, March 16th. HC Wainwright analyst M. Caufield now forecasts that the company will earn ($0.44) per share for the quarter, up from their previous forecast of […]

Mineralys Reports 2025 Results, Advances Hypertension Drug Review

RADNOR, PA — Mineralys Therapeutics Inc. (Nasdaq: MLYS) reported its fourth-quarter and full-year 2025 financial results and said the U.S. Food and Drug Administration has accepted its new drug application for lorundrostat, a treatment for hypertension. The FDA assigned a Prescription Drug User Fee Act target date of December 22, 2026, for the agency’s decision on the drug. The application seeks approval for lorundrostat to treat hypertension in…

Mineralys Therapeutics, Inc. (MLYS) Stock Analysis: Exploring A 91.90% Upside Potential

Mineralys Therapeutics, Inc. (NASDAQ: MLYS) is catching the attention of investors with its impressive potential upside of 91.90%. As a healthcare player in the biotechnology industry, this biopharmaceutical company is focused on developing innovative treatments for diseases linked to dysregulated aldosterone, including hypertension and chronic kidney disease. ### Company Overview Headquartered in Radnor, Pennsylvania, Mineralys Therapeutics, In…